CS236674B2 - Manufacturing method of calcareous salt of oxaprozine - Google Patents

Manufacturing method of calcareous salt of oxaprozine Download PDF

Info

Publication number
CS236674B2
CS236674B2 CS823052A CS305282A CS236674B2 CS 236674 B2 CS236674 B2 CS 236674B2 CS 823052 A CS823052 A CS 823052A CS 305282 A CS305282 A CS 305282A CS 236674 B2 CS236674 B2 CS 236674B2
Authority
CS
Czechoslovakia
Prior art keywords
oxaprozin
calcium
salt
sodium
tablet
Prior art date
Application number
CS823052A
Other languages
Czech (cs)
English (en)
Inventor
Ahmed Saeed Mughal
Original Assignee
Wyeth John & Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother Ltd filed Critical Wyeth John & Brother Ltd
Publication of CS236674B2 publication Critical patent/CS236674B2/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CS823052A 1981-04-28 1982-04-28 Manufacturing method of calcareous salt of oxaprozine CS236674B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8113074 1981-04-28

Publications (1)

Publication Number Publication Date
CS236674B2 true CS236674B2 (en) 1985-05-15

Family

ID=10521427

Family Applications (1)

Application Number Title Priority Date Filing Date
CS823052A CS236674B2 (en) 1981-04-28 1982-04-28 Manufacturing method of calcareous salt of oxaprozine

Country Status (24)

Country Link
US (2) US4465838A (fr)
EP (1) EP0063884B1 (fr)
JP (1) JPS57181072A (fr)
KR (1) KR880000871B1 (fr)
AT (1) ATE14015T1 (fr)
AU (1) AU544975B2 (fr)
CA (1) CA1169867A (fr)
CS (1) CS236674B2 (fr)
DD (1) DD202017A5 (fr)
DE (1) DE3264400D1 (fr)
DK (1) DK150604C (fr)
ES (1) ES511730A0 (fr)
FI (1) FI71314C (fr)
GR (1) GR75913B (fr)
HU (1) HU185276B (fr)
IE (1) IE52909B1 (fr)
IL (1) IL65443A (fr)
MY (1) MY8700599A (fr)
NZ (1) NZ200247A (fr)
PH (1) PH18053A (fr)
PL (1) PL136322B1 (fr)
PT (1) PT74794B (fr)
ZA (1) ZA822355B (fr)
ZW (1) ZW7482A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6726928B2 (en) * 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
ATE299699T1 (de) * 1996-05-20 2005-08-15 Searle Llc Arzneimittel enthaltend oxaprozin natriumsalz, kaliumsalz, oder tris(hydroxymethyl)aminomethansalz
US7358254B2 (en) * 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
US20060251689A1 (en) * 2005-03-30 2006-11-09 Astion Development A/S Treatment or prevention of pruritus
AU2006228869A1 (en) * 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
CN102197163B (zh) * 2008-08-26 2014-03-05 多尔夫凯塔尔化学制品（I）私人有限公司 一种用于抑制酸腐蚀的新型添加剂及其使用方法
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
GB1245087A (en) * 1967-10-26 1971-09-02 Wyeth John & Brother Ltd Heterocyclic compounds
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles

Also Published As

Publication number Publication date
FI71314B (fi) 1986-09-09
KR880000871B1 (ko) 1988-05-28
DK150604C (da) 1987-12-07
KR830009772A (ko) 1983-12-23
HU185276B (en) 1984-12-28
JPS57181072A (en) 1982-11-08
MY8700599A (en) 1987-12-31
ES8307230A1 (es) 1983-07-01
CA1169867A (fr) 1984-06-26
DK183582A (da) 1982-10-29
EP0063884B1 (fr) 1985-06-26
US4532253A (en) 1985-07-30
ATE14015T1 (de) 1985-07-15
GR75913B (fr) 1984-08-02
IE52909B1 (en) 1988-04-13
ZW7482A1 (en) 1983-11-09
NZ200247A (en) 1984-10-19
EP0063884A1 (fr) 1982-11-03
US4465838A (en) 1984-08-14
FI71314C (fi) 1986-12-19
PH18053A (en) 1985-03-18
ZA822355B (en) 1983-11-30
PT74794B (en) 1983-11-07
IE820766L (en) 1982-10-28
DE3264400D1 (en) 1985-08-01
IL65443A0 (en) 1982-07-30
PT74794A (en) 1982-05-01
IL65443A (en) 1985-04-30
ES511730A0 (es) 1983-07-01
AU544975B2 (en) 1985-06-27
PL136322B1 (en) 1986-02-28
FI821324L (fi) 1982-10-29
DD202017A5 (de) 1983-08-24
JPH0261466B2 (fr) 1990-12-20
PL236145A1 (fr) 1982-12-06
FI821324A0 (fi) 1982-04-15
AU8237882A (en) 1982-11-04
DK150604B (da) 1987-04-13

Similar Documents

Publication Publication Date Title
EP0476696B1 (fr) Composition pharmaceutique à goût amélioré ayant des particules poreuses et procédé de préparation d'une telle composition pharmaceutique
DE60128683T2 (de) Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
SA94150373A (ar) صياغات جديدة واستخدام صياغة في علاج و/أوالوقاية من اضطرابات معينة
RU2004123624A (ru) Сухие гранулированные композиции азитромицина
EA002331B1 (ru) Фармацевтический препарат, содержащий клодронат в качестве активного ингредиента и агрегат микрокристаллической целлюлозы и диоксида кремния в качестве наполнителя
KR920006909B1 (ko) 니트렌디핀을 함유하는 고상 약제의 제조 방법
CS236674B2 (en) Manufacturing method of calcareous salt of oxaprozine
KR20010071765A (ko) 제약학적 레보타이록신 제제
EP0380021B1 (fr) Système stabilisateur pour formes solides de doses
SK106094A3 (en) Pharmaceutical agent
DE3517820A1 (de) Pharmazeutische praeparate mit antihypertensiver und kardioprotektiver wirkung
EP1292303B1 (fr) Formulation pharmaceutique stable contenant du torsemide modification ii
EP1292598B1 (fr) Procede de sechage de l'amoxicilline
US2768115A (en) Penicillin-aspirin tablets
DE3922441A1 (de) Ibuprofen- und s-(+)-ibuprofen-zubereitungen und verfahren zu ihrer herstellung
EP1407766B1 (fr) Compositions pharmaceutiques contenant un sel d'acide alendronique
GB2097389A (en) Oxazole derivative
JPH0737383B2 (ja) 胃酸分泌抑制剤含有固型製剤
PL196046B1 (pl) Postać krystaliczna monohydratu cytrynianu (2S,3S)-N-(2-metoksy-5-t-butylofenylo)metylo-2-difenylometylo-1-azabicyklo[2.2.2]oktano-3-aminy, środek farmaceutyczny, zastosowanie tej postaci krystalicznej i sposób wytwarzania tej postaci krystalicznej
JPH0251527B2 (fr)
JPH0469126B2 (fr)
GB2148894A (en) Aluminium salts of oxazole derivatives
JPS61200942A (ja) ビタミンＫ↓２−ジメチル−β−シクロデキストリン包接化合物
JP2001064159A (ja) 複合顆粒剤
TW202227047A (zh) 甲狀腺荷爾蒙的製劑化方法